Larvol Veri

CANCER:

Lung Adenocarcinoma

Related cancers:

‹

Non Small Cell Lung Cancer (1831)

Lung Non-Squamous Non-Small Cell Cancer (61)

Lung Non-Small Cell Squamous Cancer (53)

Non Small Cell Lung Cancer (1831)

Lung Non-Squamous Non-Small Cell Cancer (61)

Lung Non-Small Cell Squamous Cancer (53)

›

EGFR exon 19 deletion + T790M + C797S + HER-2 amplification EGFR exon 19 deletion + T790M + C797S + HER-2 amplification	Lung Adenocarcinoma LUAD	afatinib + rivoceranib Sensitive: C4 – Case Studies Onco Targets Ther - 1 day afatinib + rivoceranib Sensitive : C4 Onco Targets Ther - 1d
EGFR T790M + C797S EGFR T790M + C797S	Lung Adenocarcinoma LUAD	gefitinib + osimertinib Resistant: C4 – Case Studies Onco Targets Ther - 1 week gefitinib + osimertinib Resistant : C4 Onco Targets Ther - 1wk
EGFR T790M + C797S EGFR T790M + C797S	Lung Adenocarcinoma LUAD	osimertinib + anlotinib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week osimertinib + anlotinib Sensitive : C4 Onco Targets Ther - 1wk
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials Tumori - 3 weeks crizotinib Sensitive : C3 Tumori - 3wk
NCOR2-NTRK1 fusion + TMB-H NCOR2-NTRK1 fusion + TMB-H	Lung Adenocarcinoma LUAD	camrelizumab Resistant: C4 – Case Studies BMC Pulm Med - 3 weeks camrelizumab Resistant : C4 BMC Pulm Med - 3wk
NCOR2-NTRK1 fusion + TMB-H NCOR2-NTRK1 fusion + TMB-H	Lung Adenocarcinoma LUAD	larotrectinib Sensitive: C4 – Case Studies BMC Pulm Med - 3 weeks larotrectinib Sensitive : C4 BMC Pulm Med - 3wk
No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1
MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	cetuximab + afatinib Sensitive: C3 – Early Trials cetuximab + afatinib Sensitive : C3
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES